Zynex, Inc. (ZYXI) announced on Tuesday that it has received FDA clearance for its new prescription-only TensWave device.This device boasts a portable and user-friendly design, aimed at providing effective pain relief through Transcutaneous Electrical Nerve Stimulation (TENS) therapy. This technology offers patients a safe, effective, and drug-free option for managing pain.The TensWave enhances Zynex’s product lineup, joining the established NexWave device. It offers a premium TENS solution that meets specific insurance reimbursement criteria.Currently, ZYXI’s stock is trading at $7.75, a decline of 1.40%, on the Nasdaq.The material has been provided by InstaForex Company – www.instaforex.com
Latest posts by Insta Forex (see all)
- Roche’s Xofluza Reduces Influenza Transmission In Phase III Study - September 19, 2024
- UK Car Registrations Plummet in August, Marking a Sharp Year-over-Year Decline - September 19, 2024
- Germany’s Car Registrations Plummet by Nearly 28% Year-Over-Year in August 2024 - September 19, 2024
